Publications by authors named "Alison R Roth"
Background: Patients with polyneuropathies typically have demyelination and/or axonal degeneration in peripheral nerves. Currently, there is a lack of imaging biomarkers to track the changes in these pathologies.
Purpose: To develop and evaluate the reliability of a multiparametric quantitative magnetic resonance imaging (qMRI) method of peripheral nerves in the leg.
Manual disease delineation in full-body imaging of patients with multiple metastases is often impractical due to high disease burden. However, this is a clinically relevant task as quantitative image techniques assessing individual metastases, while limited, have been shown to be predictive of treatment outcome. The goal of this work was to evaluate the efficacy of deep learning-based methods for full-body delineation of skeletal metastases and to compare their performance to existing methods in terms of disease delineation accuracy and prognostic power.
View Article and Find Full Text PDFCandidate imaging biomarkers for PMP22-related inherited neuropathies.
Ann Clin Transl Neurol
July 2022
Objective: Charcot-Marie-Tooth type 1A (CMT1A) and hereditary neuropathy with liability to pressure palsy (HNPP) are caused by mutations to the peripheral myelin protein 22 (PMP22) gene. A need exists for sensitive and reliable biomarkers of progression and treatment response. Magnetic resonance imaging (MRI) metrics of nerve pathology and morphology were investigated for this purpose.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on understanding treatment response variability in men with progressive metastatic castration-resistant prostate cancer using quantitative total bone imaging (QTBI) with F-NaF PET/CT scans.
- Twenty-three men were treated with enzalutamide, and their bone response was monitored over time, showing a decrease in bone lesion activity during treatment but an increase at progression.
- The results suggest that many bone lesions continue to respond positively to enzalutamide therapy even after signs of progression, indicating a possible benefit in targeting nonresponding lesions instead.
Purpose: We previously reported the safety and immunologic effects of a DNA vaccine (pTVG-HP [MVI-816]) encoding prostatic acid phosphatase (PAP) in patients with recurrent, nonmetastatic prostate cancer. The current trial evaluated the effects of this vaccine on metastatic progression.
Patients And Methods: Ninety-nine patients with castration-sensitive prostate cancer and prostate-specific antigen (PSA) doubling time (DT) of less than 12 months were randomly assigned to treatment with either pTVG-HP co-administered intradermally with 200 μg granulocyte-macrophage colony-stimulating factor (GM-CSF) adjuvant or 200 μg GM-CSF alone six times at 14-day intervals and then quarterly for 2 years.
Background: Whole-body assessments of F-NaF positron emission tomography (PET)/computed tomography (CT) provide promising quantitative imaging biomarkers of metastatic castration-resistant prostate cancer (mCRPC). This study investigated whether the distribution of metastases across anatomic regions is prognostic of progression-free survival.
Patients And Methods: Fifty-four mCRPC patients with osseous metastases received baseline NaF PET/CT.